The recurrently wheezing preschool child-benign or asthma in the making?

Annals of Allergy, Asthma & Immunology

December 2015 Volume 115, Issue 6, Pages 463-470  CME Review

Overall Purpose
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for ContinuingMedical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Planning Committee Members:
Leonard B. Bacharier, MD (Author)
Jonathan A. Bernstein, MD (Annals CME Subcommittee)
Guha Krishnaswamy, MD (Annals CME Subcommittee)
John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Describe the various trajectories of wheezing in early life and their associations with subsequent asthma
Identify risk factors that contribute to persistence of wheezing from early life through childhood

Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute/Medical College of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, HRSA and National Institutes of Health (NIH). L.B. Bacharier has been a consultant to DBV Technologies, Genentech, Merck, Novartis, Sanofi and Teva; has been a speaker for and has received honoraria from AstraZeneca, Genentech, Novartis and Teva; and has received research grants from National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. J.A. Bernstein, and G. Krishnaswamy, have nothing to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. No unapproved/ investigative use of a product/device is discussed.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
12/01/2015
Course expires: 
11/30/2017
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
12/01/2015
Course expires: 
11/30/2017

Price

Cost:
$0.00
Please login or create an account to take this course.